Understanding how cancer cells evade the immune system
Official title: Deciphering Mechanisms Underlying Cancer Immunogenicity
Run by Institut Claudius Regaud · NCT03958240 · Data updated 2026-11-12
This study is trying to understand how cancer cells hide from the immune system by looking at blood and tumor samples from 900 patients with different types of solid tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1100 (estimated) |
| Sponsor | Institut Claudius Regaud Academic / other |
| Locations | 3 sites (Toulouse and 2 other locations) |
| Status | Recruiting |
| Started | January 17, 2020 |
| Main results expected | January 2033 |
| Study ends | January 2033 |
| Registry record updated | September 15, 2025 |
| Trial ID | NCT03958240 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically confirmed local or metastatic solid malignant tumors or pre-invasive cervical high-grade dysplasia.
✕Probably not a fit
Patients with a known history of viral infections like Hepatitis B, Hepatitis C, or HIV may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial is a multicentric, prospective cohort study involving 900 patients with various solid tumors, including head and neck, ovarian, and cervical cancers, as well as glioblastoma. The study aims to investigate the expression of PD-1 in T cells to better understand cancer immunogenicity. Participants will provide biological specimens such as tumor and blood samples over a 5-year period. Each tumor type will be analyzed as an independent cohort to gather comprehensive data on immune response mechanisms.
Why it matters
Potential benefit: If successful, this study could lead to improved immunotherapy strategies for patients with solid tumors.
How similar studies have gone: Other studies have shown promise in understanding immune evasion in cancer, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient with histologically documented local or metastatic solid malignant tumor (head and neck, ovarian, cervical, and other tumor types including, but not limited to glioblastoma, NSCLC and anal cancer) or patients with pre-invasive cervical high grade dysplasia (CIN II or III) 2. Age ≥ 18 years at the time of study entry 3. Patient followed within a standard of care procedure or clinical trial 4. ECOG Performance status 0-2 5. Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol 6. Patient affiliated to a Social Health Insurance in France 7. Patient may participate to other clinical trials Exclusion Criteria: 1. Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or Hanta virus 2. Any condition contraindicated with blood sampling procedures required by the protocol (including Hemoglobin \< 8g/dl) 3. Patient pregnant, or breast-feeding 4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure 5. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship
Where it's running
-
Hopital Larrey
Toulouse, France Recruiting -
Hopital Rangueil
Toulouse, France Recruiting -
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France Recruiting
Study contacts
- Study coordinator: Alejandra MARTINEZ
- Email: martinez.alejandra@iuct-oncopole.fr
- Phone: +33 5 31 15 53 66
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
-
Virtual exercise program to preserve function and prevent disability during chemotherapy
This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.
-
Testing MDX2001 for advanced solid tumors
This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
Concurrent Immunotherapy and SBRT for Stage IV Cancers
This trial tests whether giving stereotactic body radiation therapy (SBRT) alongside approved immunotherapies can safely help control advanced cancers that have spread, while patients continue their planned treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.